clinical trial · NCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.·phase1·recruiting·n = 126
NeoplasmsJNJ-87704916CetrelimabStandard of Care PD(L)-1
brief summary
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
started
Apr 10, 2024
primary completion
Nov 8, 2028
completion
Aug 26, 2032
last updated
May 8, 2026
official title
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol